Biosimilar

The drug category has an estimated annual sale of $122 million in the US. Shares of Lupin were marginally higher in the session, sharply rising after the announcement was made public.

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

This approval will provide significant additional capacity to address patients' needs across markets in Europe, the company said in a statement.

Biocon Biologics, Sandoz sign pact to distribute adalimumab biosimilar Humira in Japan

Adalimumab BS for subcutaneous injection is a biosimilar of Humira, offering therapeutic solutions for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease and ulcerative colitis

Biocon Biologics receives European Commission approval for ophthalmology biosimilar Yesafili

Yesafili, a biosimilar of aflibercept, will enhance treatment options for patients suffering from eye conditions like macular degeneration in the European region

Dr Reddy's completes clinical studies of key biosimilar, step closer to launching in US, Europe

The company will collaborate with partner Fresenius Kabi to commercialise the proposed biosimilar for treating illnesses such as arthritis and non-Hodgkin's lymphoma in the US but plans to take the product directly to EU and other regions

Dr Reddy’s completes phase 1 study of key anti-rheumatic biosimilar drug

The company is now initiating a global study to compare the efficacy, safety and immunogenicity of the proposed medication.

Lupin: Pricing erosion intensifies in US

Near-term growth visibility is low due to a lack of major product launches, aggravating pricing erosion and input cost pressure for Lupin

Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward

Cadila’s stock was primed by a series of potential roll outs to meet the COVID-19 challenge. Beyond COVID, the company is steadily building up its injectable and biosimilars portfolio - the areas to look at for the longer term.

Cadila: All in for COVID while keeping a tab on complex pharma

Cadila's stock has been primed by a series of potential rollouts to meet the COVID challenge

Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy

The Natrol sale will help Aurobindo Pharma focus on the core generic drug and injectable businesses

Plan to enter EU market with Insulin Glargine in second half of the year: Biocon

We are now ready to enter the European market with our Insulin Glargine as a biosimilar, in the second half of this year, said Kiran Mazumdar Shaw, CMD, Biocon.

Glenmark gets USFDA nod to test anti-asthma biosimilar omalizumab on humans

Glenmark Pharmaceuticals, on Tuesday, said the US drug regulator cleared the company's investigational new drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar, which will assess its pharmacokinetics in comparison to Novartis anti-asthma biologic XOLAIR or omalizumab in healthy adult volunteers between 18-65 years of age.

Aurobindo sees R&D costs to double as it gets into biosimilars

The company on Friday said it plans to spend about USD 80 million in next two years as it prepares to take the lead biosimilar molecule bevacizumab into clinical trial.

Aurobindo forays into biosimilars with Swiss acquisition

Aurobindo Pharma forayed into biosimilars with acquisition of four cell culture derived biosimilar products from Switzerland-based TL Biopharmaceutical AG. As part of the deal. TL will supply all the developmental data for four molecules and Aurobindo will develop and market these products globally.

I don't see Trump's views affecting Indian drug cos: Biocon CMD

Following US president-elect Donald Trump‘s explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.

USFDA to review Biocon-Mylan's biosimilar drug for breast cancer

Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.

Fosun Pharma best fit due to global presence, size: Gland Pharma

Fosun Pharma complements the injectables platform created by Gland Pharma and provides scope to expand into front-end marketing, said Gland's Vice Chairman and Managing Director Ravi Penmetsa.

Regulatory issues discussed in Feb meet with US, Europe: DRL

Company will continue with tie-ups for biosimilar products. These will first be launched in India and then in other markets, says Satish Reddy, Chairman of Dr Reddy‘s Lab.

HC allows Biocon, Mylan to continue manufacturing cancer drugs

The Delhi High Court has allowed pharma firms, Biocon Ltd and Mylan Pharmaceuticals Pvt Ltd, to continue with manufacture and marketing of their breast cancer drug under their brand names 'CANMAb' and 'HERTRAZ'.

We try to launch products at one-fifth global price: Cadila

Zydus Cadila launched the biosimilar version of Adalimumab, which is the world's first biosimilar made end-to-end in India. Sharvil Patel, Deputy MD, Cadila Healthcare says the important this is to look at access or affordability.

Biocon-Mylan start phase-3 global trials for drug Glargine

The size of Glargine is expected to be around USD 3-4 billion globally.

Cipla launches biosimilar for rheumatic disorders in India

Drug major Cipla today said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in India.

Mylan-Biocon partnership gives access to key markets: Shaw

Biocon chief, Kiran Majumdar Shaw told CNBC-TV18 in an exclusive that the Mylan partnership on biosimilars gives them access to certain key markets that could help the company take advantage of the available opportunity in those markets.